



PRESS RELEASE

eko.ai granted patent for automated heart ultrasound analysis workflow and signs deals with AstraZeneca and Janssen as rebranded Us2.ai

SINGAPORE, 29 September 2020 -- eko.ai, a fast-growing, Sequoia India and EDBI backed, medtech startup using machine learning to automate the analysis of echocardiograms (echos), or ultrasound images of the heart, announced on World Heart Day several significant milestones, including renaming the company to Us2.ai.

Us2.ai is pleased to announce the grant of a US Patent No. 10,702,247 for its automated clinical workflow that recognizes and analyzes 2-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction and prognosis of heart disease.

"Us2 software transforms what today is a slow, manual and error prone process into less than two minutes, one click and zero variability, delivering a complete echo report," said James Hare, CEO and co-founder of Us2.ai. "The potential of our AI platform has led to multiple research collaborations, and we're delighted to welcome both AstraZeneca and Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, as strategic partners in our mission to automate the fight against cardiovascular disease."

The collaboration with Janssen will focus on automating echocardiography analyses to facilitate identification of pulmonary hypertension. The AstraZeneca research collaboration will refine algorithms for the diagnosis of heart failure, as well as test access to automated echo analysis with Point-of-Care solutions for people with heart failure.

Heart failure (HF) is a global health problem, affecting >64 million people worldwide. In developed countries, the prevalence of diagnosed HF is estimated at 1-2% of the adult population, with the true prevalence including unrecognized HF even higher. Echo is a cardiologist's top tool of choice to safely image the heart, and the key diagnostic test required for the diagnosis of HF. However, conventional echo is time consuming, expensive and only undertaken by highly trained specialists.

"Since our founding three years ago, we've been driven by the conviction that AI can help broaden access to diagnosis and potentially lifesaving treatment," said Yoran Hummel,

President and co-founder of Us2.ai. “These announcements reflect the rapid pace of our development and commitment to providing the next generation of ultrasound to us all.”

The company’s decision support software is currently undergoing validation for regulatory review in multiple regions, and is available for research use.

About Us2.ai

Us2.ai uses machine learning to automate the fight against heart disease. The company’s software tools improve cardiovascular research and the performance of clinical trials using echocardiography, the safest and most common cardiac imaging modality. eko.ai connects institutions and imaging labs around the world on a platform of ready to use automation tools for view classification, segmentation and federated learning across diverse, anonymous patient and disease cohorts. Us2.ai was formerly known as eko.ai.

Media Contact:
Laura Cooke
Explore Communications
+65 9115 7617

SOURCE Us2.ai